Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.
about
Current status and future directions of botulinum neurotoxins for targeting pain processingStructures of engineeredClostridium botulinumneurotoxin derivativesBotulinum neurotoxin devoid of receptor binding domain translocates active protease.Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.What next for botulism vaccine development?Therapeutic use of botulinum toxin in migraine: mechanisms of action.Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.Towards new uses of botulinum toxin as a novel therapeutic toolIncreased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons.O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain SyndromeA botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axisClinical uses of botulinum neurotoxins: current indications, limitations and future developmentsBotulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.Progress in cell based assays for botulinum neurotoxin detectionEngineering botulinum neurotoxin to extend therapeutic intervention.Targeted secretion inhibitors-innovative protein therapeuticsBotulinum neurotoxin for pain management: insights from animal models.Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering.Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells.Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function.Targets for botulinum toxin in the lower urinary tract.Brain-derived neurotrophic factor in urinary continence and incontinence.Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014).New intraprostatic injectables and prostatic urethral lift for male LUTS.Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.Intravesical injection of botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome: 10 years of experience at a single center in China.Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domainThe changed image of botulinum toxin.Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.Engineering botulinum neurotoxin domains for activation by toxin light chain.Engineering of Botulinum Neurotoxins for Biomedical Applications.
P2860
Q26778129-B41811F4-1E6F-42A6-A9B3-E22B3F0BB818Q27675943-EB2AB186-EEB0-4B10-99F8-B2A9F5E79C1DQ33394567-491DBD31-9C52-44A7-A518-E9186751D6E9Q33915263-E11E099F-0F6D-4660-A5F1-758A316B3E8BQ34154494-A212FCDA-7C61-4CEF-B133-60A4121C7CD8Q34343808-3B48A7D8-E962-4E7A-B145-8EF992B793F8Q34419654-A05AB017-6E75-4331-AA0E-E0D27D576C7DQ34612698-703F32A9-6FFD-485F-8037-C84D57F0B0F5Q35187559-6A98CD9E-108C-44DD-A171-D31A1189C4F5Q35534477-02B41777-7745-468D-964B-F73B59886301Q35548169-DDF78F3F-08EF-4EF3-A6EB-D0164CE62B7EQ35996597-97D1B4AD-15CB-47C5-BBC0-A234A7593347Q36190743-C8E5D1AD-191B-40FB-AA0C-662643CA6234Q36395728-E12992FA-4EAA-4672-8037-F86498C79F49Q36511574-CA2B1DA9-42A4-4508-A6F9-585107FD0957Q36818335-44BAB7C5-0C61-44D3-97FC-7059ADC382AFQ37224285-1B0EE659-70A3-42BB-9091-EAC181AE252FQ37954277-A56E6F06-F130-4345-AF9F-74547EBF5792Q37954278-B674E7C7-72CE-43D2-B3E8-C48F5F40922DQ37954285-25822AAD-995C-4BB1-8E66-B8C82B3B6858Q37954286-D290F408-E5B4-43D9-919B-BBC5ED53FFBCQ38080382-21AD335D-60AE-406D-897F-A4F22EBA187AQ38115266-4D022E2E-39A0-45B3-AB2B-68D712C2D0E4Q38249927-35801DF1-4A68-45D4-AE0A-7C838CF609B4Q38406085-042732EC-11EA-4F6C-B206-0580735B4797Q38551294-48D9D5AA-BBC3-4FDE-BE09-3D788D6B7687Q39207459-54EA60E9-5CC7-4F15-B5D8-E5C483054BFAQ40265659-121FCA71-8C51-4629-B407-B033D846757FQ41478422-71790A16-0DF6-4FB7-ACE8-90D5FF7CA0E4Q42315993-DB5853A0-4D4A-48E9-923B-A5EE598FE11AQ42780619-0186302D-1C97-464C-8C6F-DD572D63152BQ45370003-C63C43F1-1F4A-4073-9B10-C4DEE5C9D5A1Q53201125-85EF495B-1EA7-486A-AB10-13C87A664ED8Q55460011-67AA4662-073B-48B9-906C-BD092E5FFFEF
P2860
Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@en
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@nl
type
label
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@en
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@nl
prefLabel
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@en
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@nl
P2093
P2860
P356
P1476
Inhibition of release of neuro ...... Erythrina cristagalli lectin.
@en
P2093
Anthony Dickenson
Clifford C Shone
Elizabeth R Kirby
Frances C G Alexander
G Mark Green
Hilary J Moulsdale
John A Chaddock
John R Purkiss
Keith A Foster
Lorna M Friis
P2860
P304
34846-34852
P356
10.1074/JBC.M202902200
P407
P577
2002-07-08T00:00:00Z